Lauren Pinter-Brown, MD, of UCI Health, Chao Family Comprehensive Cancer Center, Orange, CA, talks on a response criterion for clinical trials assessing treatments for cutaneous T-cell lymphoma (CTCL) which 3 contemporary trials have utilized and outlines these trials. Dr Pinter-Brown talks on the Phase III ALCANZA study (NCT01578499) of brentuximab vedotin versus methotrexate or bexarotene and the Phase III MAVORIC study (NCT01728805) on mogamulizumab versus vorinostat for relapsed/refractory CTCL. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.

свернуть